Evolution of the Average Target: Merck & Co., Inc.

Evolution of the Target Price: Merck & Co., Inc.

Changes in Analyst Recommendations: Merck & Co., Inc.

edfe4b2c847fe295cc15a6d1875e.u6pHRaxwiNeBH2KzcrnoQ59q2p1nOxH4ZcUC6RVmScQ._e4wM9VdwIfJThX1BvOQHKZYuaofFiiKMJ11iEQzH5Hu3AIV6hfb4slsWg~92f8cb85f617cbbc832fef8890219d30
02-13 Merck Shares Rise After Deutsche Bank Upgrade MT
02-13 Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115 MT
02-13 Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115 MT
02-12 Argus Adjusts Price Target on Merck to $130 From $110, Maintains Buy Rating MT
02-11 Daiwa Securities Adjusts PT on Merck & Co. to $120 From $86, Maintains Neutral Rating MT
02-11 Analyst recommendations: Cloudflare, Mattel, Qualcomm, Gilead, Hasbro… Zonebourse
02-10 Rothschild & Co Redburn Adjusts Price Target on Merck & Co. to $140 From $135, Maintains Buy Rating MT
02-06 Guggenheim Adjusts Price Target on Merck & Co to $140 From $122, Maintains Buy Rating MT
02-05 Analyst recommendations: Corteva, Snap, Alphabet, Eli Lilly, PayPal, Qualcomm… Zonebourse
02-04 Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says MT
02-04 Bernstein Adjusts Price Target on Merck to $100 From $95, Maintains Market Perform Rating MT
02-04 Leerink Partners Adjusts Price Target on Merck to $128 From $124, Maintains Outperform Rating MT
02-04 Goldman Sachs Adjusts Price Target on Merck to $133 From $120, Maintains Buy Rating MT
02-04 BMO Capital Adjusts Price Target on Merck & Co. to $135 From $130, Maintains Outperform Rating MT
02-04 Scotiabank Adjusts PT on Merck & Co. to $136 From $120, Maintains Sector Outperform Rating MT
02-04 Morgan Stanley Adjusts Price Target on Merck & Co. to $109 From $101, Maintains Equalweight Rating MT
02-04 Wells Fargo Adjusts Price Target on Merck & Co. to $135 From $125, Maintains Overweight Rating MT
02-04 Cantor Fitzgerald Adjusts Price Target on Merck & Co. to $120 From $116, Maintains Neutral Rating MT
02-04 Citigroup Adjusts Price Target on Merck & Co to $120 From $115, Maintains Neutral Rating MT
02-03 Scotiabank Raises Merck Price Target to $136 From $120 MT
01-27 Cantor Fitzgerald Adjusts Price Target on Merck & Co. to $116 From $83, Keeps Neutral Rating MT
01-27 Citigroup Adjusts Price Target on Merck & Co. to $115 From $110, Keeps Neutral Rating MT
01-26 Berenberg Raises Price Target on Merck to $115 From $95, Keeps Hold Rating MT
01-26 Analyst recommendations: Amazon, Intel, Netflix, Merck, SanDisk… Zonebourse
01-22 JPMorgan Adjusts Price Target on Merck & Co. to $125 From $120, Maintains Overweight Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+2.73%
+15.98%
-4.96%
+5.91%
-3.18%
+2.33%
-9.84%
+22.41%
-6.94%
-1.14%
Average +2.33%
Weighted average by Cap. +3.84%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
121.57USD
Average target price
124.88USD
Spread / Average Target
+2.73%
High Price Target
150.00USD
Spread / Highest target
+23.39%
Low Price Target
100.00USD
Spread / Lowest Target
-17.74%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Deutsche Bank Securities
Argus
Daiwa Securities
Rothschild & Co Redburn
Guggenheim
Bernstein
Leerink Partners
Goldman Sachs
BMO Capital
Citigroup
Cantor Fitzgerald
Wells Fargo Securities
Morgan Stanley
Scotiabank
Berenberg Bank
JPMorgan Chase
TD Cowen
Wolfe Research
UBS
HSBC
Jefferies & Co.
DBS Bank
Redburn Atlantic
Truist Securities
CFRA
Barclays
Zacks Investment Research
Societe Generale
BofA Securities
Atlantic Equities
Credit Suisse
SVB Securities LLC
Cowen
SVB Leerink
RBC Capital Markets
RBC Randall Stanicky
JPMORGAN
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
121.57USD
Average target price
124.88USD
Spread / Average Target
+2.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. Consensus Merck & Co., Inc.